These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29201193)

  • 41. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal hepatic encephalopathy: A review.
    Nardone R; Taylor AC; Höller Y; Brigo F; Lochner P; Trinka E
    Neurosci Res; 2016 Oct; 111():1-12. PubMed ID: 27153746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Gut flora and gut-derived endotoxin in minimal hepatic encephalopathy].
    Zhai HQ; Fan H; Geng JW; Tao J; Xun LT; Wang Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 Feb; 22(2):104-7. PubMed ID: 24735591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
    Direkze S; Jalan R
    Dig Dis; 2015; 33(4):562-9. PubMed ID: 26159274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review.
    Wang SC; Chen YC; Chen SJ; Lee CH; Cheng CM
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico.
    Bajaj JS; Torre A; Rojas ML; Fagan A; Nandez IE; Gavis EA; De Leon Osorio O; White MB; Fuchs M; Sikaroodi M; Gillevet PM
    Liver Int; 2020 Jun; 40(6):1395-1407. PubMed ID: 32181561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis.
    Kim SS; Eun JW; Cho HJ; Song DS; Kim CW; Kim YS; Lee SW; Kim YK; Yang J; Choi J; Yim HJ; Cheong JY
    Aliment Pharmacol Ther; 2021 Feb; 53(4):540-551. PubMed ID: 33264437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial.
    Pratap Mouli V; Benjamin J; Bhushan Singh M; Mani K; Garg SK; Saraya A; Joshi YK
    Hepatol Res; 2015 Aug; 45(8):880-9. PubMed ID: 25266207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.
    Saab S; Suraweera D; Au J; Saab EG; Alper TS; Tong MJ
    Liver Int; 2016 Jul; 36(7):986-93. PubMed ID: 26561214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats.
    Jia L; Zhang MH
    World J Gastroenterol; 2005 Feb; 11(6):908-11. PubMed ID: 15682492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy.
    Rivera-Flores R; Morán-Villota S; Cervantes-Barragán L; López-Macias C; Uribe M
    Nutrition; 2020 May; 73():110693. PubMed ID: 32065881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut microbiota and hepatic encephalopathy.
    Dhiman RK
    Metab Brain Dis; 2013 Jun; 28(2):321-6. PubMed ID: 23463489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy.
    Mancini A; Campagna F; Amodio P; Tuohy KM
    Food Funct; 2018 Mar; 9(3):1373-1388. PubMed ID: 29485654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.
    Kaji K; Saikawa S; Takaya H; Fujinaga Y; Furukawa M; Kitagawa K; Ozutsumi T; Kaya D; Tsuji Y; Sawada Y; Kawaratani H; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Antibiotics (Basel); 2020 Mar; 9(4):. PubMed ID: 32235367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.